Compare BMHL & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMHL | QTTB |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | Hong Kong | United States |
| Employees | 9 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.9M | 80.0M |
| IPO Year | N/A | 2018 |
| Metric | BMHL | QTTB |
|---|---|---|
| Price | $3.58 | $5.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 2.4K | ★ 322.6K |
| Earning Date | 03-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 136.78 |
| EPS | N/A | ★ 2.42 |
| Revenue | N/A | ★ $53,737,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $66.66 | ★ $2.35 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.72 | $1.40 |
| 52 Week High | $4.48 | $8.05 |
| Indicator | BMHL | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 50.59 | 49.99 |
| Support Level | $3.24 | $5.51 |
| Resistance Level | $3.89 | $6.37 |
| Average True Range (ATR) | 0.19 | 0.70 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 84.09 | 36.28 |
Bluemount Holdings Ltd through its operating subsidiaries, it is a Hong Kong-based consulting and advisory and financial services provider, as well as trader of commodities such as luxury timepieces. The financial services includes underwriting and placing services, securities dealing and brokerage services, and asset management services. It provides comprehensive consulting and advisory services on business development strategies to its diverse clientele. Generally, the company provides consulting and advisory business for the following segments: Corporate Finance; and Strategic Communications.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).